Role of PML in Cell Growth and the Retinoic Acid Pathway
10.1126/science.279.5356.1547
Crossref journal-article
American Association for the Advancement of Science (AAAS)
Science (221)
Abstract

ThePMLgene is fused to the retinoic acid receptor α (RARα) gene in chromosomal translocations associated with acute promyelocytic leukemia (APL). Ablation of murine PML protein by homologous recombination revealed that PML regulates hemopoietic differentiation and controls cell growth and tumorigenesis. PML function was essential for the tumor-growth–suppressive activity of retinoic acid (RA) and for its ability to induce terminal myeloid differentiation of precursor cells. PML was needed for the RA-dependent transactivation of thep21WAF1/CIP1gene, which regulates cell cycle progression and cellular differentiation. These results indicate that PML is a critical component of the RA pathway and that disruption of its activity by the PML-RARα fusion protein may be important in APL pathogenesis.

Bibliography

Gang Wang, Z., Delva, L., Gaboli, M., Rivi, R., Giorgio, M., Cordon-Cardo, C., Grosveld, F., & Paolo Pandolfi, P. (1998). Role of PML in Cell Growth and the Retinoic Acid Pathway. Science, 279(5356), 1547–1551.

Authors 8
  1. Zhu Gang Wang (first)
  2. Laurent Delva (additional)
  3. Mirella Gaboli (additional)
  4. Roberta Rivi (additional)
  5. Marco Giorgio (additional)
  6. Carlos Cordon-Cardo (additional)
  7. Frank Grosveld (additional)
  8. Pier Paolo Pandolfi (additional)
References 50 Referenced 418
  1. Grignani F., et al., Blood 83, 10 (1994); (10.1182/blood.V83.1.10.10) / Blood by Grignani F. (1994)
  2. Pandolfi P. P., Haematologica 81, 472 (1996). / Haematologica by Pandolfi P. P. (1996)
  3. Longo L., et al., J. Exp. Med. 172, 1571 (1990); (10.1084/jem.172.6.1571) / J. Exp. Med. by Longo L. (1990)
  4. Borrow J., Goddard A. D., Sheer D., Solomon E., Science 249, 1577 (1990); (10.1126/science.2218500) / Science by Borrow J. (1990)
  5. de Thé H., Chomienne C., Lanotte M., Degos L., Dejean A., Nature 347, 558 (1990); (10.1038/347558a0) / Nature by de Thé H. (1990)
  6. Pandolfi P. P., et al., Oncogene 6, 1285 (1991); / Oncogene by Pandolfi P. P. (1991)
  7. de Thé H., et al., Cell 66, 675 (1991); (10.1016/0092-8674(91)90113-D) / Cell by de Thé H. (1991)
  8. ; A. Kakizuka et al. ibid. p. 663; A. D. Goddard
  9. Borrow J., Freemont P. S., Solomon E., Science 254, 1371 (1991); (10.1126/science.1720570) / Science by Borrow J. (1991)
  10. Pandolfi P. P., et al., EMBO J. 11, 1397 (1992). (10.1002/j.1460-2075.1992.tb05185.x) / EMBO J. by Pandolfi P. P. (1992)
  11. Chambon P., FASEB J. 10, 940 (1996). (10.1096/fasebj.10.9.8801176) / FASEB J. by Chambon P. (1996)
  12. Smith M. A., Parkinson D. R., Cheson B. D., Friedman M. A., J. Clin. Oncol. 10, 839 (1992); (10.1200/JCO.1992.10.5.839) / J. Clin. Oncol. by Smith M. A. (1992)
  13. ; L. J. Gudas M. B. Sporn A. B. Roberts The Retinoids: Cellular Biology and Biochemistry of the Retinoids (Raven New York 1994).
  14. Dyck J., et al., Cell 76, 333 (1994); (10.1016/0092-8674(94)90340-9) / Cell by Dyck J. (1994)
  15. ; K. Weis et al. ibid. p. 345; M. H. M. Koken et al. EMBO J. 13 1073 (1994); (10.1002/j.1460-2075.1994.tb06356.x)
  16. Stadler M., et al., Oncogene 11, 2565 (1995); / Oncogene by Stadler M. (1995)
  17. ; C. Lavau et al. ibid. p. 871; K. Nason-Burchenal et al. Blood 88 3926 (1996). (10.1182/blood.V88.10.3926.bloodjournal88103926)
  18. Kastner P., et al., EMBO J. 11, 629 (1992); (10.1002/j.1460-2075.1992.tb05095.x) / EMBO J. by Kastner P. (1992)
  19. Perez A., et al., ibid. 12, 3171 (1993); / ibid. by Perez A. (1993)
  20. 10.1016/0092-8674(93)80044-F
  21. PML phage clones were obtained from a 129Sv mouse strain genomic library. The targeting vector contains herpes simplex virus–thymidine kinase (TK) and TK-Neo selectable markers (8) the latter of which replaces 94 base pairs of PML exon 2 encoding the PML RING-finger domain [
  22. Fagioli M., et al., Oncogene 7, 1083 (1992); / Oncogene by Fagioli M. (1992)
  23. ] and is flanked by a 2.0-kb Apa I–Nar I fragment containing PML intron 1 and a small portion of exon 2 and a 4.0-kb Nar I–Eco RI fragment corresponding to a part of PML exon 2 and intron 2. The Not I linearized vector was electroporated into AB1 ES cells and double selection was carried out as described (8). Resistant clones were screened by Southern (DNA) blotting with the 5′ and 3′ external and internal probes as shown in Fig. 1A. Germline-transmitting chimeric males obtained from two independent PML +/− euploid ES cell clones were bred with 129Sv females to generate PML +/− mice for intercrossing. A PML rabbit antiserum was used for detection of the endogenous murine PML protein [
  24. Borden K. L. B., et al., EMBO J. 14, 1532 (1995)]. (10.1002/j.1460-2075.1995.tb07139.x) / EMBO J. by Borden K. L. B. (1995)
  25. P. P. Pandolfi et al. Nature Gen. 11 40 (1995). (10.1038/ng0995-40)
  26. M. Gaboli et al. in preparation.
  27. Peripheral blood counts were performed for PML +/+ ( n = 28) and PML −/− ( n = 20) sex- and age- (2 to 3 months old) matched syngeneic (129Sv) littermates. Differential counts of myeloid and lymphoid subpopulations from PML +/+ ( n = 24) and PML −/− ( n = 22) mice were carried out on Wright-Giemsa–stained PB smears. Differential counts of three or four smears per animal were scored for a total of at least 300 cells.
  28. The following antibodies (PharMingen San Diego CA) in single or double staining were used for flow-cytometric analysis: hemopoietic stem cells or progenitors (c-Kit and CD34) T lymphocytes [Thy1 CD4 CD8 CD3 CD2 CD24 T cell receptor (TCR) αβ and TCRγδ] B lymphocytes (CD2 CD24 B220 and αIγ) and myeloid cells (Mac-1 Gr-1 and Ly-6C). If required cells were preincubated with an antibody to mouse FcγII/III receptors (Fc Block); 10 5 cells from PML +/+ ( n = 9) and PML −/− ( n = 9) sex- and age-matched syngeneic (129Sv) littermates were analyzed in three independent experiments. The reduction of granulocytes and monocytes in the BM of PML −/− mice was demonstrated by a 10 to 20% reduction of Mac-1–positive ( P < 0.03) or Gr-1–positive ( P < 0.02) (monocytic and granulocytic) Mac-I–positive and Gr-1–positive ( P < 0.01) (granulocytic) and Mac-1–positive and Gr-1–negative ( P < 0.02) or Ly-6C–positive ( P < 0.03) (monocytic) cells. No other difference was observed with any other antibody. Differential counts on cytospin smears also showed a marked reduction of granulocytes (PML −/− 12 ± 3%; PML +/+ 29 ± 5%; P < 0.01) and monocytes (PML −/− 0.1 ± 0.1%; PML +/+ 0.5 ± 0.2%; P < 0.02) in the BM of PML −/− mice with no notable decrease or accumulation of early hemopoietic precursors (blasts + promyelocytes + metamyelocytes + myelocytes) (PML −/− 5.2 ± 2%; PML +/+ 5.6 ± 1.7%) and a relative increase of erythroblasts.
  29. Mu Z. M., Chin K. V., Liu J. H., Lozano G., Chang K. S., Mol. Cell. Biol. 14, 6858 (1994); / Mol. Cell. Biol. by Mu Z. M. (1994)
  30. Koken M. H. M., et al., Oncogene 10, 1315 (1995); / Oncogene by Koken M. H. M. (1995)
  31. Liu J. H., Mu Z. M., Chang K. S., J. Exp. Med. 181, 1965 (1995); (10.1084/jem.181.6.1965) / J. Exp. Med. by Liu J. H. (1995)
  32. Le X. F., Yang P., Chang K. S., J. Biol. Chem. 271, 130 (1996). (10.1074/jbc.271.1.130) / J. Biol. Chem. by Le X. F. (1996)
  33. Mouse primary embryonic fibroblasts were isolated from embryos at 13.5 or 15.5 days of gestation. For growth curve experiments 10 5 cells per well were seeded in six-well plates in Dulbecco's minimum essential medium with 20% fetal bovine serum (FBS) and counted. Nine independent experiments were carried out from three different MEF preparations. Doubling time was calculated from the slope of the best fit line of the logarithm of cell number as a function of time. DNA synthesis was measured by incorporation of [ 3 H]thymidine (2 μCi/ml) in five independent experiments. For clonogenic efficiency 3 × 10 3 MEFs in three independent experiments were distributed on 60-mm dishes and the number of colonies (>10 cells) was scored after 8 and 16 days (14). For cell cycle analysis subconfluent cultures of MEFs were labeled for 4 hours with 10 μM bromodeoxyuridine (BrdU) (Sigma) and analyzed by two-dimensional flow cytometry (14).
  34. Conzen S. D., Cole C. N., Oncogene 11, 2295 (1995); / Oncogene by Conzen S. D. (1995)
  35. Serrano M., et al., Cell 85, 27 (1996). (10.1016/S0092-8674(00)81079-X) / Cell by Serrano M. (1996)
  36. Z. G. Wang and P. P. Pandolfi unpublished data.
  37. The backs of PML +/+ and PML −/− sex- and age- (6 to 10 weeks old) matched syngeneic (129Sv) littermates ( n = 24 for each group in two different experiments) were treated with a single application of DMBA (25 μg in 200 μl of acetone) followed by biweekly application of TPA (200 μl of 0.1 μM solution in acetone) [
  38. Kemp C. J., Donehower L. A., Bradley A., Balmain A., Cell 74, 813 (1993); (10.1016/0092-8674(93)90461-X) / Cell by Kemp C. J. (1993)
  39. ]. Treatment with TPA was terminated after 15 weeks. The number of papillomas (over 2 mm in diameter) on each mouse was scored weekly. All papillomas were taken for histological examination 36 weeks after the initiation with DMBA. The difference in the number of papillomas observed in PML −/− and PML +/+ mice was statistically significant from the 12th week of promotion ( P values: 12th week P < 0.01; 13th week P < 0.02; 14th week P < 0.01; 15th week P < 0.05; 16th week P < 0.01; 17th week P < 0.02). The effects of a systemic dose of DMBA were studied as follows: DMBA (2.5 mg in 50 μl of liquid petrolatum) was injected into the left lobe of the surgically exposed salivary gland of PML −/− ( n = 25) and PML +/+ ( n = 25) sex- and age- (6 to 10 weeks old) matched syngeneic (129Sv) anesthetized littermates in two different experiments. Mice were followed for 1 year and then killed. Postmortem analysis revealed that tumors in PML −/− mutants developed in mice that had not yet developed infections.
  40. Barka T., van der Noen H., Michelakis A. M., Schenkein I., Lab. Invest. 42, 656 (1980). / Lab. Invest. by Barka T. (1980)
  41. Douer D., Koeffler H. P., Exp. Cell. Res. 138, 193 (1982); (10.1016/0014-4827(82)90105-7) / Exp. Cell. Res. by Douer D. (1982)
  42. Gratas C., Menot M. L., Dresch C., Chomienne C., Leukemia 7, 1156 (1993). / Leukemia by Gratas C. (1993)
  43. To score for colony-forming units–erythrocyte (CFU-E) we plated BM cells at a concentration of 2 × 10 5 cells per dish in MethoCult M3330 (Stemcell Technology Vancouver Canada) and counted colonies after 2 days. For burst-forming units–erythrocyte (BFU-E) CFU–granulocyte and monocyte (CFU-GM) and CFU–granulocyte monocyte erythrocyte and megakaryocyte (CFU-MIX) BM cells were plated at a concentration of 3 × 10 4 cells per dish in MethoCult M3430 (Stemcell Technology). Colonies were scored at days 7 and 14. Five independent experiments were carried out from PML −/− ( n = 7) and PML +/+ ( n = 7) sex- and age-matched syngeneic littermates. BM cultures with or without RA: To score CFU-E and BFU-E we plated BM cells as above and counted them at days 2 and 6 respectively; for CFU-GM 5 × 10 4 cells were plated in medium with 30% FBS granulocyte and monocyte colony-stimulating factor (GM-CSF) (20 ng/ml) and granulocyte CSF (G-CSF) (50 ng/ml) and scored after 6 days. Retinoic acid in dimethyl sulfoxide (DMSO) was added at a final concentration of 1 μM. Untreated cells were cultured in the presence of the same concentration of DMSO. PML −/− PML-RARα BM cells were harvested from mice obtained by intercrossing PML −/− mice and PML-RARα transgenic mice [
  44. He L. Z., et al., Proc. Natl. Acad. Sci. U.S.A. 94, 5302 (1997); (10.1073/pnas.94.10.5302) / Proc. Natl. Acad. Sci. U.S.A. by He L. Z. (1997)
  45. ]. These experiments were performed on healthy mice before the occurrence of leukemia. Nine independent experiments were carried out from PML −/− ( n = 11) PML +/+ ( n = 11) and PML −/− PML-RARα ( n = 2) sex- and age-matched syngeneic littermates.
  46. Liu M., Lee M. H., Cohen M., Bommakanti M., Freedman L. P., Genes Dev. 10, 142 (1996); (10.1101/gad.10.2.142) / Genes Dev. by Liu M. (1996)
  47. Liu M., Iavarone A., Freedman L. P., J. Biol. Chem. 271, 31723 (1996). (10.1074/jbc.271.49.31723) / J. Biol. Chem. by Liu M. (1996)
  48. L. Delva et al. in preparation.
  49. Manshouri T., et al., Blood 89, 2507 (1997). (10.1182/blood.V89.7.2507) / Blood by Manshouri T. (1997)
  50. We thank M. Barna A. Bradley A. Bygrave G. Cattoretti R. Dalla Favera T. Delohery E. Dzierzak M. Fagioli P. S. Freemont D. Gandini N. Hawe M. Lindenbaum L. Longo R. Lovell-Badge L. Luzzatto S. Nicolis P. G. Pelicci and E. Solomon for materials assistance and advice. Partially supported by the Associazione Italiana per la Ricerca sul Cancro (P.P.P. R.R. and M.G.) and the Ligue Nationale contre le Cancer of France (L.D.). P.P.P. is a Scholar of the Leukemia Society of America. Supported by the Sloan-Kettering Institute (CA-08748) and National Institutes of Health (CA 71692 awarded to P.P.P.).
Dates
Type When
Created 23 years, 1 month ago (July 27, 2002, 5:42 a.m.)
Deposited 8 months, 3 weeks ago (Dec. 8, 2024, 1:21 p.m.)
Indexed 1 month, 2 weeks ago (July 14, 2025, 11:33 p.m.)
Issued 27 years, 5 months ago (March 6, 1998)
Published 27 years, 5 months ago (March 6, 1998)
Published Print 27 years, 5 months ago (March 6, 1998)
Funders 0

None

@article{Gang_Wang_1998, title={Role of PML in Cell Growth and the Retinoic Acid Pathway}, volume={279}, ISSN={1095-9203}, url={http://dx.doi.org/10.1126/science.279.5356.1547}, DOI={10.1126/science.279.5356.1547}, number={5356}, journal={Science}, publisher={American Association for the Advancement of Science (AAAS)}, author={Gang Wang, Zhu and Delva, Laurent and Gaboli, Mirella and Rivi, Roberta and Giorgio, Marco and Cordon-Cardo, Carlos and Grosveld, Frank and Paolo Pandolfi, Pier}, year={1998}, month=mar, pages={1547–1551} }